1 Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating

2 in Colombia

- 3 **Short title:** Substitutions in SARS-CoV-2 Spike and nucleocapsid proteins
- 4
- 5 Carlos Franco-Muñoz^{a, c,*}, Diego A. Álvarez-Díaz^{a, b}, Katherine Laiton-Donato^a,
- 6 Magdalena Wiesner^d, Patricia Escandón^d, José A. Usme-Ciro^{a,e}, Nicolás D.
- 7 Franco-Sierra^f, Astrid C. Flórez-Sánchez^{9,} Sergio Gómez-Rangelⁱ, Luz D.
- 8 Rodríguez-Calderonⁱ, Juliana Barbosa-Ramirezⁱ, Erika Ospitia-Baezⁱ, Diana M.
- 9 Walteros^h, Martha L. Ospina-Martinez^j, Marcela Mercado-Reyes.^{a, b, k}
- 10 a. Unidad de Secuenciación y Genómica. Dirección de Investigación en Salud
- 11 Pública, Instituto Nacional de Salud. Bogotá 111321, Colombia
- 12 b. Grupo de Salud Materna y Perinatal. Dirección de Investigación en Salud
- 13 Pública, Instituto Nacional de Salud. Bogotá 111321, Colombia
- 14 c. Grupo de Parasitología. Dirección de Investigación en Salud Pública, Instituto
- 15 Nacional de Salud. Bogotá 111321, Colombia
- 16 d. Grupo de Microbiología, Dirección de Investigación en Salud Pública, Instituto
- 17 Nacional de Salud, Bogotá, Colombia
- 18 e. Centro de Investigación en Salud para el Trópico–CIST, Universidad
- 19 Cooperativa de Colombia, Santa Marta. Santa Martha 470003, Colombia
- 20 f. Programa Ciencias de la Biodiversidad, Instituto de Investigación de Recursos
- 21 Biológicos Alexander von Humboldt, Bogotá 111311, Colombia.
- 22 g. Dirección de Redes en Salud Pública, Instituto Nacional de Salud. Bogotá -
- 23 111321, Colombia

- 24 h. Dirección de Vigilancia en Salud Pública, Instituto Nacional de Salud. Bogotá -
- 25 **111321, Colombia**
- i. Grupo de Virología, Dirección de Redes en Salud Pública, Instituto Nacional de
- 27 Salud. Bogotá 111321, Colombia
- j. Dirección General, Instituto Nacional de Salud. Bogotá 111321, Colombia
- 29 k. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud. Bogotá
- 30 111321, Colombia
- 31

32 Symbol

- 33 *Corresponding author: Grupo de Parasitología. Dirección de Investigación en
- 34 Salud Pública, Instituto Nacional de Salud. Bogotá 111321, Colombia. E-mail:
- 35 <u>cefrancom@unal.edu.co</u>
- 36

37 Abstract

38 Introduction: SARS-CoV-2 is a new member of the genus Betacoronavirus, 39 responsible for the COVID-19 pandemics. The virus crossed the species barrier 40 and established in the human population due to its ability to exploit the ACE 41 receptor for virus entry, which is present and abundant in several tissues, including 42 the lung and respiratory tract, gastrointestinal tract and hearth. Virus interaction 43 with the cellular receptor is mediated by the surface protein, known as Spike. 44 Another structural protein of major importance in the Nucleocapsid, directly 45 interacting with the viral RNA to form the ribonucleocapsid, considered a 46 multifunctional protein, and being the target of the most molecular diagnostics 47 assays. Objective: To describe the frequency of substitutions in spike and 48 nucleocapsid proteins of SARS-CoV-2 circulating in Colombia and evaluate the 49 frequency of these substitutions in SARS-CoV-2 sequences from other countries of 50 South America. Materials and methods: Samples of 43 patients were included for

51 viral RNA detection by real-time RT-PCR using the Charité-Berlin protocol for the 52 amplification of the SARS-CoV-2 E and RdRp genes. Genome sequences were 53 obtained through the Oxford Nanopore and Illumina MiSeq technologies, following 54 the artic.network "nCoV-2019 sequencing protocol". Available genomes were 55 consulted from GISAID, GenBank, and Genome sequence archive (GSA) and a 56 total of 371 genomes sequences from South America were included. The genome 57 sequences were aligned with the Muscle tool using the MEGA X software. 58 Substitution matrices of the Colombian sequences respect to the reference 59 genome (NC 045512) at the nucleotide and amino acid levels were generated for 60 the spike and nucleocapsid gene. Results: substitution D614G in the amino acid sequence of spike protein was found 61 in 86.7% of the Colombian sequences; substitutions G181V and D936Y in 2.3%, 62 63 respectively. Five substitutions were found in the nucleocapsid protein, with 64 substitution R203K and G204R being the most frequent (13.95%) in Colombia. 65 The substitutions D614G in Spike and R203K-G204R in nucleocapsid have a 66 frequency of 83% and 28% respectively in sequences from South America. 67 Conclusion: Non-synonymous substitutions were found in the spike and 68 nucleocapsid proteins in Colombian genomes, the most frequent being D614G in 69 Spike and R203K-G204R in nucleocapsid. These substitutions are frequent in the genomes reported for other South American countries. It is necessary to continue 70 71 with genomic surveillance of the changes in Spike and Nucleocapsid proteins 72 during the SARS-CoV-2 pandemic in Colombia and South America, even more 73 considering that these proteins are the most commonly used antigen in serological 74 tests. 75 76 **Highlights**

- The spike and nucleocapsid proteins of SARS-CoV-2 circulating in
- 78 Colombia and South-American countries have similar patterns of non-synonymous
- 79 substitutions

• Substitutions D614G in Spike and R203K-G204R in Nucleocapsid are the

- 81 most frequent in Colombia and South-American countries
- 82

83 Key words

- 84 SARS-CoV-2, spike, nucleocapsid, Colombia, Non-synonymous substitutions,
- 85 Outbreak lineages.
- 86

87 **1. Introduction**

88 The recently emerged SARS-CoV-2 responsible for the coronavirus disease 2019 89 (COVID-19) pandemic, has increased significantly in the number of cases and 90 deaths, so that daily, about 70,000 new cases are reported globally 91 (WHO, 2020a, 2020c). In Colombia, the first case of COVID-19 was announced by 92 the Nation's Ministry of Health on March 6, in a traveler from Italy, after which the 93 number of patients has exceeded 10,000 and over 500 deaths (INS, 2020). The 94 SARS-CoV-2 genome consist of a single, positive-stranded RNA (ssRNA[+]), with 95 29,903 nucleotides long. This virus has shown an extraordinary infectiousness and 96 transmission capacity in the human population (He et al., 2020), even exploring 97 other vertebrate species (Shi et al., 2020). The SARS-CoV-2 genome has nine 98 open reading frames (ORFs); the first one, subdivided in ORF1a and ORF1b by 99 ribosomal frameshifting, encodes the polyproteins pp1a and pp1ab which are 100 processed into non-structural proteins involved in subgenomic/genome length RNA 101 synthesis and virus replication. Structural proteins, Spike (S), Envelope (E), 102 Membrane (M), and Nucleocapsid (N) are encoded in subgenomic mRNA 103 transcripts within ORFs 2, 4, 5, and 9, respectively (SIB, 2020; Yount et al., 2005) 104 105 Spike protein, a type I membrane glycoprotein, is the most exposed viral protein 106 recognized by the cellular receptor angiotensin-2-converting enzyme (ACE2) 107 during the infection of the lower respiratory tract and considered the main inducer

108 of neutralizing antibodies. The N protein is associated with the RNA genome to

109 form the ribonucleocapsid and is abundantly expressed during infection. Both N

and S proteins are highly immunogenic and most commercial COVID-19 diagnostic

assays (molecular and immunologic) target these proteins (Alvarez-Diaz et al.,

112 2020; Lee, Lin, Renia, & Ng, 2020).

113

114 Furthermore, non-synonymous mutations in the S and N proteins have been

115 reported, their implications in the potential emergence of antigenically distinct

and/or more virulent strains remain to be studied, although it was reported that

117 mutations in the receptor-binding domain (RBD) at the S protein of SARS-CoV-

related viruses disrupt the antigenic structure and binding activity of RBD to ACE2

(Du et al., 2009) Similarly, how non-synonymous mutations could impact the

120 antibody response and the specificity and sensitivity of serological tests for COVID-

121 19 diagnosis is unknown. Thus, identifying variable sites at these proteins can

122 provide a valuable resource for choosing the target antigens for the development of

123 SARS-CoV-2 vaccines, therapeutics and diagnostic tests (Du et al., 2009;

124 Jacofsky, Jacofsky, & Jacofsky, 2020). The objective of this study is to describe the

125 frequency of substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2

126 circulating in Colombia and evaluate the frequency of these substitutions in SARS-

127 CoV-2 sequences from other countries of South America.

128

129 **2.** Materials and methods

130 **2.1 Ethics**

This work was developed according to the national law 9/1979, decrees 786/1990 and 2323/2006, which establishes that the Instituto Nacional de Salud (INS) from Colombia is the reference lab and health authority of the national network of laboratories and in cases of public health emergency or those in which scientific research for public health purposes as required. The INS is authorized to use the biological material for research purposes, without informed consent, which includes

- 137 the anonymous disclosure of results. This study was performed following the
- 138 ethical standards of the Declaration of Helsinki 1964 and its later amendments.
- 139 The information used for this study comes from secondary sources of data that
- 140 were previously anonymized and do protect patient data.

141 **2.2 Patients and samples**

- 142 Nasopharyngeal swab samples from patients with suspected SARS-CoV-2
- 143 infection were processed for RNA extraction using the automated MagNA Pure LC
- nucleic acid extraction system (Roche Diagnostics GmbH, Mannheim, Germany)
- and viral RNA detection was performed by real-time RT-PCR using the SuperScript
- 146 III Platinum One-Step Quantitative RT-qPCR kit (Thermo Fisher Scientific,
- 147 Waltham, MA, USA), following the Charité-Berlin protocol (Corman et al., 2020) for
- 148 the amplification of the SARS-CoV-2 E (betacoronavirus screening assay) and
- 149 RdRp (SARS-CoV-2 confirmatory assay) genes.

150 **2.3 Complete genome sequencing of SARS-CoV-2 through NGS**

- 151 NGS of SARS-CoV-2 from 43 patients was performed using the amplicon-based
- 152 Illumina and Nanopore sequencing approaches, ARTIC network protocol (Quick,
- 153 2020a). Following cDNA synthesis with SuperScript IV reverse transcriptase
- 154 (Thermo Fisher Scientific, Waltham, MA, USA) and random hexamers (Thermo
- 155 Fisher Scientific, Waltham, MA, USA), a set of 400-bp tiling amplicons across the
- 156 whole genome of SARS-CoV-2 were generated using the primer schemes nCoV-
- 157 2019/V3 (Quick, 2020a).

- 158 SARS-CoV-2 specific oligonucleotides were used for the generation of amplicons
- 159 by means of a high-fidelity DNA polymerase (Q5® High-Fidelity DNA Polymerase -
- 160 (New England Biolabs Inc., UK, EB), in order to avoid the introduction of artificial
- 161 substitutions.
- 162 **2.4 Sequence Analysis**
- 163 Databases as GISAID, NCBI, and GSA were consulted and a total of 371
- 164 sequences were included. The South American sequences were aligned with the
- 165 Muscle tool (Edgar, 2004) using the MEGA X software (Kumar, Stecher, & Tamura,
- 166 2016). Substitutions matrices of SARS-CoV-2 sequences deposited in GISAID
- 167 (Table 1), compared to the reference genome (NC_045512) at the nucleotide and
- amino acid levels were generated for the Spike and Nucleocapsid genes and
- 169 proteins. The Colombian sequences were analyzed to determine the frequency of
- amino acid changes in Spike and Nucleocapsid proteins. Based on Phylogenetic
- 171 Assignment of Named Global Outbreak LINeages (PANGOLIN)
- 172 <u>https://github.com/hCoV-</u> 2019/pangolin different lineages were defined in
- 173 Colombian genomes.
- 174 **3. Results**

3.1 Non-synonymous substitutions in the Spike and Nucleocapsid proteins

- 177 Three amino acid changes were observed in the spike protein of Colombian SARS-
- 178 CoV-2 sequences compared to the reference sequence (NC_045512.2). Spike
- 179 protein substitution D614G is present in 81% (35/43) of the sequences reported in
- 180 this study. The following substitutions were also found in lower frequency: G181V

2.3% (1/43) and D936Y 2.3% (1/43) (Table 1). In nucleocapsid protein, five amino
acid changes were found when Colombian genomes reported in this study were
compared to the reference sequence (NC_045512.2). The most frequent changes
were R203K and G204R in 13.95% (6/43) of the sequences. Amino acid changes
R191C, R209I and G238C were found in 4.65% (2/43), 4.65% (2/43) and 6.97%
(3/43) of the Colombian sequences, respectively (Table 1). Some nucleotide
substitutions were synonymous.

189 Nonsynonymous substitution D614G in the spike protein was the most frequent 190 observed in Colombian sequences included in this study. Genomic resource 191 databases such as NCBI, GISAID and GSA were consulted to determine if the 192 predominant substitutions in genomes reported in Colombia were present in other 193 countries in South America. A total of 86 genomes from Colombia, 29 from 194 Argentina, 92 from Brazil, 143 from Chile, 4 from Ecuador, 2 from Peru and 11 from Uruguay were reported as of May 19th, 2020. G614 of SARS-CoV-2 was 195 196 frequent in Argentina, Brazil, Chile, Colombia and Peru, with 80-100% of the 197 reported sequences (Figure 1A). However, in Ecuador and Uruguay, D614G was 198 observed in less percentages, possibly related to the low number of genomes 199 reported or to the introduction history of SARS-CoV-2 in these countries. Finally, 200 some reported genomes had indeterminate nucleotides at the site of the 201 substitution and could not be included in the analysis.

202

3.2 Spatiotemporal distribution of substitutions in Spike and Nucleocapsid

A temporal analysis of the distribution of D614G in the 131 Colombian reported genomes, including the genomes reported in this study, was performed using the available collection sample data in the associated metadata (Figure 1B). Since the first case report date in Colombia and during March 2020, 14% of Colombian sequences exhibited aspartate at position 614 in the spike protein (D614), while in April 2020, the frequency reduced to 4%.

210

211 Nonsynonymous substitutions R203K and G204R (13.95%), which are the

hallmarks of the B.1.1 lineage, were the most frequent substitutions in

213 Nucleocapsid protein of Colombian sequences included in this study. Both

substitutions are frequent in Argentina and Brazil, present in the 55% of the

reported sequences (Fig. 1C). In Peru, Ecuador and Chile the frequency were

similar to reported for Colombia, while in Uruguay the substitution was not present.

217 Temporal analysis of the distribution of the R203/G204 and K203/R204 subtypes of

the Nucleocapsid for the 131 Colombian genomes shows that the frequency of the

219 K203/R204 subtype was 9% in March 2020, and became 19% in April 2020 (Fig.

1D), suggesting that the frequency of this substitution could increase over time and

reach values similar to those reported for Brazil and Chile.

222

Regarding the other nonsynonymous substitutions that were observed in less frequency, the G181V substitution of the spike protein, was observed in one

225 Colombian sequence and in two sequences from Brazil, while the D936Y

substitution of spike protein was not observed in other genomes from South

America. The R191C substitution in the nucleocapsid protein was observed in two

Colombian sequences and in another Argentina sequence, R209I was observed in
nine sequences from Chile and finally, G238C was exclusive to three Colombian
sequences.

231

3.3 Nonsynonymous substitutions and circulating lineages in Colombia

- 233 In the analysis of the nonsynonymous substitutions in the Spike protein of
- 234 Colombian sequences, the G181V substitution was observed in a Colombian
- sequence classified as lineage B.1. The D614G substitution was observed in
- sequences classified as lineage B.1, in sublineages B.1.1, B.1.3, B.1.5, B.1.8, and
- B.1.11 and lineage B.2. The D936Y substitution was observed in sequences
- classified as of lineage B.1.5. As for Nucleocapsid protein, the R191C substitution
- was observed in two Colombian sequences of lineage B.1.5. The R203K and
- 240 G204R substitutions were observed in sequences classified as lineage B.1. Finally
- the R209I substitution in sequences classified as lineage B.2.5 and G238C
- substitution in sequences classified as the lineage A.5.
- **4. Discussion**

The first COVID-19 case in Colombia was confirmed on March 6, 2020, from a

person who entered the country from Italy on February 26, 2020. In June 1th, a total

- de 30.493 cases have been reported with 969 deaths (INS, 2020). This study
- evidenced the presence of the D614G substitution in spike protein in 89.6%
- 248 (112/125) of sequences since March 10, 2020, while strains circulating in previous
- 249 dates reveal the original substitutions reported in Wuhan (Bhattacharyya et al.,
- 250 2020), including the first Colombian strain sequenced from a symptomatic patient

sampled on March 11, 2020, linked to the second generation of a transmissionchain starting with an imported case from Spain.

253

254 D614G was detected in 86% of sequences from March, 2020 and in 96% of

sequences from April, 2020, being present in most of the geographical

departments of Colombia with genomic information available. D614G has been

found in 13 departments located from the Caribbean coast to the Amazon region in

258 only 3 months since the first case was reported in Colombia. While several studies

have emphasized the potential role of the D614G substitution in favoring the virus

transmissibility (Becerra-Flores & Cardozo, 2020; Bhattacharyya et al., 2020;

Brufsky, 2020), our data only suggest a founder effect determined by the multiple

introduction of G614-bearing B.1 sublineages.

263

In-silico analysis of D614G substitution in Spike suggests a more stable union with

the ligand ACE2 (Becerra-Flores & Cardozo, 2020; Brufsky, 2020; Nakashima,

266 2020). Preliminary results suggest that the presence of D614G statistically

correlate with the mean number of deaths occurred in several European countries

and Brazil (Becerra-Flores & Cardozo, 2020). Korber et al proposes an association

with infectivity, rapid dispersion and high viral load in infected patients (Korber et

al., 2020). Kim et al suggested that this substitution could affect the ability to

activate long-term immune response against SARS-CoV-2. Antigenicity analysis of

amino acids 613 to 621 from Spike protein related decreases in the epitope

273 recognition in B cells, in charge of stimulating adaptive immune response by

274 producing antibodies. Therefore, this reduced immunogenicity leads to recurrent

- infections by this lineage and must be a point to consider in vaccine development
- 276 (Kim, Nguyen, Park, Park, & Chung, 2020).
- 277
- 278 On the other hand, the double substitutions R203K and G204R in the
- 279 Nucleocapsid protein was also identified in South American sequences, in 28% of
- the isolates with mutations in three consecutives nucleotides. Gupta et al reported
- this alteration in isolates from Belgium, Brazil, Peru, Mexico, Nigeria, Switzerland,
- Vietnam and India (Gupta & Mandal). Ayub observed an association between the
- presences of this substitution with case fatality (Ayub, 2020). While the most amino
- acid changes evidenced in the Spike and Nucleocapsid proteins cannot be directly
- related to a specific lineage, as has been reported in previous studies
- 286 (Bhattacharyya et al., 2020; Korber et al., 2020), the B.1.1 lineage is defined by the
- three-nucleotide mutation leading to the two consecutives amino acid changes.
- 288

RNA viruses are known to possess very high substitution rates (Li, Li, Cui, & Wu, 2020; Tang et al., 2020), leading to high genetic variability and to the action of the evolutionary mechanisms of natural selection and genetic drift. Despite some evolutionary changes may be in fact adaptive, it is important to be careful with conclusions in the absence of an experimental model to evaluate the impact of every mutation in the virus phenotype and virus-host interaction.

295

Recombinant proteins or synthetic peptides from SARS-CoV-2 derived from the reported genomic information is a well-explored alternative for the production of antigens to be used in serological tests, considering that the production of total

299 viral antigen implies biosafety challenges and the need for a BSL3 laboratory. 300 Taking into account that Spike and Nucleocapsid are the major immunogenic 301 proteins of SARS and MERS coronavirus and the first choice for producing 302 recombinant antigens (Yan, Chang, & Wang, 2020), it is essential to continue with 303 the evolutionary monitoring of genes included in the original designs of serological 304 tests, because amino acid changes can affect the conformational structure and 305 physical-chemical properties of the proteins. Considering that reduced 306 immunogenicity in Spike protein is associated with the D614G amino acid change, 307 it could also be having impact in serosurveillance studies in countries where the 308 subtype G614 is prevalent, such as Spain, where a seroprevalence of 5% was 309 registered (MSCBS, 2020).

310

5. Conclusion

312 Amino acid changes were found in the Spike and Nucleocapsid proteins in 313 Colombian genomes of SARS-CoV-2, the most frequent being D614G in Spike and 314 R203K-G204R in Nucleocapsid. These substitutions are frequent in the genomes 315 reported for other South American countries. It is necessary to continue with 316 genomic surveillance of changes in spike and nucleocapsid proteins during the 317 SARS-CoV-2 pandemic in Colombia and South America, even more considering 318 that these proteins are the most commonly antigen/target used in serological and 319 molecular tests. Identification of nucleotide substitutions, amino acid changes and 320 their frequency in the circulating virus in the region is an important information for 321 decision-making of public health, such as if a vaccine candidate is appropriate for a

- 322 specific population. Monitoring genetic variability is important for the refinement of
- 323 SARS-CoV-2 serological and molecular tests.
- 324

325 6. Acknowledgements

- 326 The authors thank the National Laboratory Network for routine virologic
- 327 surveillance of SARS-CoV-2 in Colombia. The authors thank all the Colombian and
- 328 foreign researchers who deposited genomes in GISAID's EpiFlu (TM) Database
- 329 contributing to genomic diversity and phylogenetic relationship of SARS-CoV-2.
- 330

331 Conflict of interests

- 332 The authors declare no competing interest.
- 333

334 Funding

- 335 This study was funded by the National Institute of Health, Bogota, Colombia
- 336

337 References

338 Alvarez-Diaz, D. A., Franco-Munoz, C., Laiton-Donato, K., Usme-Ciro, J. A., Franco-339 Sierra, N. D., Florez, A. C., . . . Mercado-Reyes, M. (2020). Molecular analysis of 340 several in-house rRT-PCR protocols for SARS-CoV-2 detection in the context of 341 genetic variability of the virus in Colombia. medRxiv, 2020.2005.2022.20107292. 342 doi:10.1101/2020.05.22.20107292 343 Ayub, M. I. (2020). Reporting Two SARS-CoV-2 Strains Based on A Unique 344 Trinucleotide-Bloc Mutation and Their Potential Pathogenic Difference. Published 345 online April, 19. 346 Becerra Flores, M., & Cardozo, T. (2020). SARS CoV 2 viral spike G614 mutation 347 exhibits higher case fatality rate. International Journal of Clinical Practice. 348 Bhattacharyya, C., Das, C., Ghosh, A., Singh, A. K., Mukherjee, S., Majumder, P. P., ... 349 Biswas, N. K. (2020). Global Spread of SARS-CoV-2 Subtype with Spike Protein Mutation D614G is Shaped by Human Genomic Variations that Regulate 350 351 Expression of TMPRSS2 and MX1 Genes. bioRxiv.

352	Brufsky, A. (2020). Distinct Viral Clades of SARS CoV 2: Implications for Modeling of
353	Viral Spread. Journal of Medical Virology.
354	Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Drosten,
355	C. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
356	Euro surveillance : bulletin Europeen sur les maladies transmissibles = European
357	communicable disease bulletin, 25(3), 2000045. doi:10.2807/1560-
358	7917.ES.2020.25.3.2000045
359	Du, L., He, Y., Zhou, Y., Liu, S., Zheng, BJ., & Jiang, S. (2009). The spike protein of
360	SARS-CoV—a target for vaccine and therapeutic development. Nature Reviews
361	<i>Microbiology</i> , 7(3), 226-236.
362	Edgar, R. C. (2004). MUSCLE: multiple sequence alignment with high accuracy and high
363	throughput. Nucleic Acids Res, 32(5), 1792-1797. doi:10.1093/nar/gkh340
364	Gupta, A. M., & Mandal, S. Loss of Epitopes from SARS-Cov-2 Proteins for Non-
365	synonymous Mutations: A Potential Global Threat.
366	He, X., Lau, E. H., Wu, P., Deng, X., Wang, J., Hao, X., Tan, X. (2020). Temporal
367	dynamics in viral shedding and transmissibility of COVID-19. Nature medicine,
368	26(5), 672-675.
369	INS. (2020). Coronavirus (COVID - 2019) en Colombia. Retrieved from
370	https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx
371	Jacofsky, D., Jacofsky, E. M., & Jacofsky, M. (2020). Understanding Antibody Testing for
372	COVID-19. The Journal of Arthroplasty.
373	Kim, SJ., Nguyen, VG., Park, YH., Park, BK., & Chung, HC. (2020). A Novel
374	Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their
375	Antigenicity and Immunogenicity? Vaccines, 8(2), 220.
376	Korber, B., Fischer, W., Gnanakaran, S. G., Yoon, H., Theiler, J., Abfalterer, W.,
377	Parker, M. D. (2020). Spike mutation pipeline reveals the emergence of a more
378	transmissible form of SARS-CoV-2. <i>bioRxiv</i> .
379	Kumar, S., Stecher, G., & Tamura, K. (2016). MEGA7: molecular evolutionary genetics
380	analysis version 7.0 for bigger datasets. <i>Molecular biology and evolution, 33</i> (7),
381	1870-1874.
382	Lee, C. YP., Lin, R. T., Renia, L., & Ng, L. F. (2020). Serological Approaches for
383	COVID-19: Epidemiologic Perspective on Surveillance and Control. Frontiers in
384	Immunology, 11, 879.
385	Li, J., Li, Z., Cui, X., & Wu, C. (2020). Bayesian phylodynamic inference on the temporal
386	evolution and global transmission of SARS-CoV-2. J Infect.
387	doi:10.1016/j.jinf.2020.04.016
388	MSCBS. (2020). ESTUDIO ENE-COVID19: PRIMERA RONDA ESTUDIO NACIONAL
389	DE SERO-EPIDEMIOLOGÍA DE LA INFECCIÓN POR SARS-COV-2 EN
390	ESPAÑA. Spain: Ministerio de Sanidad - España Retrieved from
391	https://www.mscbs.gob.es/ciudadanos/ene-covid/home.htm.
392	Nakashima, A. (2020). The global emergences of multiple SARS-CoV-2 sub-strains:
393	Digital annotations for human behaviors may assist automated retracing of
394	symptomatic features and origins.
395	Quick, J. (2020a). nCoV-2019 sequencing protocol. Retrieved from
396	https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w

397	Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Sun, Z. (2020).
398	Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–
399	coronavirus 2. Science, 368(6494), 1016-1020.
400	SIB. (2020). Betacoronavirus. Retrieved from
401	https://viralzone.expasy.org/764?outline=all_by_species
402	Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., Lu, J. (2020). On the origin and
403	continuing evolution of SARS-CoV-2. National Science Review.
404	doi:10.1093/nsr/nwaa036
405	WHO. (2020a). WHO Director-General's opening remarks at the media briefing on
406	COVID-19 - 11 March 2020. Retrieved from
407	https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-
408	the-media-briefing-on-covid-1911-march-2020
409 410	WHO. (2020c). Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for 2019-nCoV in humans. Retrieved from
411	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-
412	guidance/laboratory-guidance
413	Yan, Y., Chang, L., & Wang, L. (2020). Laboratory testing of SARS CoV, MERS CoV,
414	and SARS \Box CoV \Box 2 (2019 \Box nCoV): Current status, challenges, and
415	countermeasures. <i>Reviews in Medical Virology</i> , e2106.
416	Yount, B., Roberts, R. S., Sims, A. C., Deming, D., Frieman, M. B., Sparks, J., Baric,
417	R. S. (2005). Severe acute respiratory syndrome coronavirus group-specific open
418	reading frames encode nonessential functions for replication in cell cultures and
419	mice. J Virol, 79(23), 14909-14922. doi:10.1128/JVI.79.23.14909-14922.2005
420	
421	
422	
423	
723	
424	
425	
1	
426	
427	
428	
429	
430	
101	
431	

432 **Figures and Tables**

433 **Table 1.** Nucleotide substitutions and amino acid changes in the Spike and Nucleocapsid 434 proteins of 43 genomes of SARS-CoV-2 from Colombia reported in this study. Location of

the substitutions was estimated base on the reference genomic sequence NC_045512.2.

436 Left panel: nucleotides; right panel: amino acids. [?]: Uncovered nucleotide and amino acids

437 during complete genome sequencing.

	Nucleotides											ds						
	Sequence ID	S					N							S		N		
GISAID Accession ID		Spike					Nucleocapsid						Spike			Nucleocapsid		
		2 2 1 0 4 G	2 3 4 0 3 A	2 3 4 3 3	2 3 7 0 7 C	2 4 3 6 8 G		8 8 8 1	2 8 8 2 G	8 8 8 8 8 9 3 9	2 2 3 8 9 9 9 8 9 5 5 G	9 2 6 9	8 1	0 0 0 0 6 9 1 3 4 6 D D	0 0 9 1 8 9 6 1	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 2 0 4	03 98
	NC_045512_SARS-COV-2_Wuhan-Hu-1	G	_	-	C	9	C	G	G	G	5 6	C	G	_	μr		GI	K G
EPI_ISL_456118 EPI_ISL_456145 EPI_ISL_456120 EPI_ISL_456116 EPI_ISL_456126	hCoV-19/Colombia/Bello/82457/2020 hCoV-19/Colombia/Medellin/80370/2020 hCoV-19/Colombia/Barranquilla/79743/2020 hCoV-19/Colombia/Bogota/79190/2020 hCoV-19/Colombia/Bogota/84861/2020 hCoV-19/Colombia/Norte_de_Santander/80656/2020 hCoV-19/Colombia/Pereira/80245/2020		00000000	• • • •	· · ·	•	· ? · ·		•	•	· · ·	T		G . G . G . G . G . G .	- - - - -	, .	•	· · · · · · · · · · · · · · · · · · ·
EPI_ISL_456130 EPI_ISL_456131 EPI_ISL_456132 EPI_ISL_456134	hCoV-19/Colombia/Cucuta/79504/2020 hCoV-19/Colombia/Bucaramanga/79752/2020 hCoV-19/Colombia/Ibague/80202/2020 hCoV-19/Colombia/Cali/79773/2020 hCoV-19/Colombia/Cali/79779/2020	· · ·	GGGGGG	C	· · · · · ·	•	•		•	•	· · ·	•		G . G . G . G .			•	· · · · · ·
EPI_ISL_456150 EPI_ISL_456141 EPI_ISL_456136	hCoV-19/Colombia/Cali/79943/2020 hCoV-19/Colombia/Cali/79965/2020 hCoV-19/Colombia/Palmira/81271/2020 hCoV-19/Colombia/Cali/79929/2020 hCoV-19/Colombia/Cali/79930/2020		G G G G G G		?	T ?	T T		• • •	· · · · · · · · · · · · · · · · · · ·	 		· · · · ·	G . G Y G ? G . G .	· · · · · · · · · · · · · · · · · · ·	- - - -		
EPI_ISL_456149 EPI_ISL_456154 EPI_ISL_456156 EPI_ISL_456139 EPI_ISL_456142	hCoV-19/Colombia/Bogota/78390/2020 hCoV-19/Colombia/Bucaramanga/80123/2020 hCoV-19/Colombia/Tumaco/103303/2020 hCoV-19/Colombia/Barrancabermeja/94514/2020 hCoV-19/Colombia/Cali/81251/2020 hCoV-19/Colombia/Cali/81279/2020	· • • •	G G G G G G G G	· · ·	· · · ·	· · · ?	· · ·	A A A	A A A A		· · ·		V	G. G. G. G. G. G. ?	· · · ·	K K K K	R R R R R R	· · · · · · · · ·
EPI_ISL_456121 EPI_ISL_456148 EPI_ISL_456124 EPI_ISL_456124 EPI_ISL_456153 EPI_ISL_456125	hCoV-19/Colombia/Leticia/103039/2020 hCoV-19/Colombia/Cartagena/79738/2020 hCoV-19/Colombia/Cartagena/79890/2020 hCoV-19/Colombia/Popayan/80705/2020 hCoV-19/Colombia/Cienaga/101935/2020 hCoV-19/Colombia/Santa_Marta/81035/2020 hCoV-19/Colombia/Bogota/96183/2020		00000000	• • • •	· · · ·	· · ? ·			• • • •		· · ·		· · ·	G . G . G ? G . G . G .	· · · · ·	-		· · · · · · · · · · ·
EPI_ISL_456122 EPI_ISL_456129 EPI_ISL_456140 EPI_ISL_456143 EPI_ISL_456151	hCoV-19/Colombia/Cartagena/80191/2020 hCoV-19/Colombia/Pereira/82099/2020 hCoV-19/Colombia/Cartago/81264/2020 hCoV-19/Colombia/Cali/82307/2020 hCoV-19/Colombia/Cali/82320/2020	· · ·	G G G G G G G G G G		· · · ·	· · · ·	· · ·	· · · ·	· · · ·		· · ·			G. G. G. G. G.	· · · ·	-		· · · · ? · · ·
EPI_ISL_417924 EPI_ISL_456119 EPI_ISL_456123 EPI_ISL_456133	hCoV-19/Colombia/Medellin/79253/2020 hCoV-19/Colombia/Antioquia/79256/2020 hCoV-19/Colombia/Medellin/80825/2020 hCoV-19/Colombia/Manizales/79489/2020 hCoV-19/Colombia/Cali/79449/2020 hCoV-19/Colombia/Cali/96176/2020	· · ·	· · ·	· · ·	· · ·		· · ? ·		•		. T . T . T . ?			· · · · · · · · ·	· · ?	· ·		. C . C . C . ?
	hCoV-19/Colombia/Armenia/80663/2020 hCoV-19/Colombia/Armenia/79911/2020	•	•	•	T T			•		. 1 . 1	Γ. Γ.				 -		•	. .






Figure 1. Spatiotemporal distribution of the most frequently substitutions in Spike and Nucleocapsid of SARS-CoV-2. A. Distribution of subtypes D614 and G614 of spike protein in SARS-CoV-2 genomes reported as of May 19th, 2020 in Colombia and other South American countries; in red, variant D614 and in green, variant G614. B. Distribution of subtypes D614 and G614 of spike protein in SARS-CoV-2 genomes reported between March and April. 2020 in Colombia, according with the sample collection date, variant D614 and in green, variant G614. C. Distribution of subtypes R203/G204 and K203/R204 of nucleocapsid protein in SARS-CoV-2 genomes reported as of May 19th, 2020 in Colombia and other South American countries, in red, variant R203/G204 and in blue, variant K203/R204. D. Distribution of subtypes R203/G204 and K203/R204 of nucleocapsid protein in SARS-CoV-2 genomes reported between March and April, 2020 in Colombia, according with the sample collection date in Colombia, in red, variant R203/G204 and in blue, variant K203/R204.

Α.





					N	uc	le	oti	de	S			A	mi	inoacids			
				s			N							s	N			
GISAID Accession ID	Sequence ID	Spike					Nucleocapsid Z							Spike	Nucleocapsid			
	NC_045512_SARS-COV-2_Wuhan-Hu-1	2 2 1 0 4 G	2 3 4 0 3 A	2 3 4 4 3 T	2 3 7 0 7 C	2 4 3 6 8 G	2 8 4 4 C	8 8 8 1	8 8 8 2	2 2 8 8 8 8 3 9 G 0	8 8 9 9 9 8 9 5	2 9 2 6 9 C	0 0 1 8 1 G	0 C 0 C 6 9 1 3 4 6	0 1 9 1		0	
	hCoV-19/Colombia/Bello/82457/2020	-	G	-	U	9	0	9	9	00	0	0	6	G.	IN.	K C		9
						20	÷								L.	•		2
	hCoV-19/Colombia/Medellin/80370/2020	•	G	•			7		•	• •				G.	17	• •		•
	hCoV-19/Colombia/Barranquilla/79743/2020	÷	G	•	÷		•			•	•	÷	·	G.	· .	• •		•
	hCoV-19/Colombia/Bogota/79190/2020	•	G	2.5		20				•		Т		G.	·	a		·]
	hCoV-19/Colombia/Bogota/84861/2020	•	G		÷	20	÷			•		×	· ·	G.	· .	• •	2	•
	hCoV-19/Colombia/Norte_de_Santander/80656/2020	•	G	.		1	÷	121					•	G.	· .	т. с	а.	٠l
	hCoV-19/Colombia/Pereira/80245/2020		G	•		(2^{n})	4	121		a (1	·	G.	· .	$\alpha = \alpha$	12	
	hCoV-19/Colombia/Cucuta/79504/2020	•	G			\mathbb{R}^{n}							•	G.	· .			
	hCoV-19/Colombia/Bucaramanga/79752/2020	•	G	•			-			•			· -	G.	· .			
	hCoV-19/Colombia/Ibague/80202/2020	•	G	С	•		÷	•	κ.	8.6	•		•	G.	÷.			·
	hCoV-19/Colombia/Cali/79773/2020		G	7•5		123								G.	·			•
	hCoV-19/Colombia/Cali/79779/2020	•	G			>						×		G.	· .			•
	hCoV-19/Colombia/Cali/79943/2020		G	•	•	1					•			G.	· .			
	hCoV-19/Colombia/Cali/79965/2020	•	G	•		Т		121			•	÷		G Y	÷.,	a . a		
	hCoV-19/Colombia/Palmira/81271/2020		G		?	?								G?				
EPI_ISL_456136	hCoV-19/Colombia/Cali/79929/2020	•	G	•		\sim	т			•			•	G.	С			•
EPI_ISL_456137	hCoV-19/Colombia/Cali/79930/2020		G				Т							G.	С	2.5	5	
	hCoV-19/Colombia/Bogota/78390/2020		G	7•5		123				C.			\cdot	G.	•	KR		•
	hCoV-19/Colombia/Bucaramanga/80123/2020		G			\sim				C.				G.	•	KR		•
EPI_ISL_456154		Т	G	•	·	1.1				с.	•		V	G.	•	KR		•
	hCoV-19/Colombia/Barrancabermeja/94514/2020	•	G	•	·	•	÷			C.	•		•	G.	•	KR		•
	hCoV-19/Colombia/Cali/81251/2020		G	•		•		Α		С.			•	G.	•	KR	L .	
	hCoV-19/Colombia/Cali/81279/2020		G			?		Α	Α_	C.				G?		KR		
	hCoV-19/Colombia/Leticia/103039/2020		G	•		$({\mathcal A}_{i})$	÷	φ.	÷					G.	÷.	v - 0	а.	
	hCoV-19/Colombia/Cartagena/79738/2020	•	G			\sim	4	10.0	a		1.1			G.	· .	a = a		
	hCoV-19/Colombia/Cartagena/79890/2020		G			\sim								G.	· ·	$\sim -\infty$	2	
	hCoV-19/Colombia/Popayan/80705/2020		G	5.2		?		121						G?			с.	•
	hCoV-19/Colombia/Cienaga/101935/2020		G	•					8		•			G.		8.8	2	
	hCoV-19/Colombia/Santa_Marta/81035/2020		G					1.1						G.				
EPI_ISL_456147	hCoV-19/Colombia/Bogota/96183/2020		G			\sim								G.				
	hCoV-19/Colombia/Cartagena/80191/2020		G			\mathbb{R}^{n}	ų.	191			?			G.	1.	e	а.	?
	hCoV-19/Colombia/Pereira/82099/2020		G	•		10		10.1					•	G.	·			.]
	hCoV-19/Colombia/Cartago/81264/2020		G	•		\sim							- I	G.	· .			
	hCoV-19/Colombia/Cali/82307/2020		G			1.1								G.	.		с.	.]
	hCoV-19/Colombia/Cali/82320/2020		G						2					G.			5	
EPI_ISL_456117	hCoV-19/Colombia/Medellin/79253/2020					- I					Т				.			С
	hCoV-19/Colombia/Antioquia/79256/2020					\mathbb{R}^{2}					T	\mathbf{x}			·			С
	hCoV-19/Colombia/Medellin/80825/2020					\mathbb{R}^{n}	÷	121			Т	а.			1.		1	С
	hCoV-19/Colombia/Manizales/79489/2020						?				?				?			?
	hCoV-19/Colombia/Cali/79449/2020																	
EPI_ISL_456152	hCoV-19/Colombia/Cali/96176/2020																	. [
EPI_ISL_456128	hCoV-19/Colombia/Armenia/80663/2020		2		Т				7	. 1	1	12		2.7		9.9	T.	
EPI_ISL_456127	hCoV-19/Colombia/Armenia/79911/2020				Ť					1							1	.]
					-	_	_			_							_	_